Trulicity Cost in Arizona 2026: Cash Price, Insurance, Medicaid and Compounding Options

What Is the Cash Price of Trulicity in Arizona in 2026?

The cash price at Arizona retail pharmacies sits at approximately $931 per month for a four-pen supply, matching the Eli Lilly manufacturer list price. No meaningful spread exists between chains such as CVS, Walgreens, and Fry's Pharmacy because dulaglutide has no FDA-approved generic and no biosimilar currently on the U.S. market. Third-party coupon aggregators like GoodRx bring the cash price down marginally, generally to $850-$920 depending on the specific dose and zip code, but that gap is small relative to the annual burden.

Dulaglutide was approved by the FDA in September 2014 for glycemic control in adults with type 2 diabetes, with the cardiovascular risk-reduction indication added in 2020 based on the REWIND trial. The drug's mechanism, GLP-1 receptor agonism, drives strong appetite suppression and insulin secretion, but Eli Lilly has not released the patent to generic manufacturers, and no 505(b)(2) pathway product has cleared FDA review as of this writing. [1]

For patients paying entirely out of pocket, $931/month equals $11,172 per year, a figure that exceeds the average Arizona household's annual grocery spend. That reality makes understanding every savings avenue non-negotiable before filling a first prescription.

The FDA Orange Book lists dulaglutide under NDA 125469. No generic applicant has received tentative or final approval. [2]

Dose does not change the monthly copay at most pharmacies. Whether a patient takes 0.75 mg (the starting dose) or 4.5 mg (the maximum approved dose), each box contains four single-dose pens covering a four-week supply, and the retail price is the same.

Does Arizona Medicaid (AHCCCS) Cover Trulicity?

Arizona Medicaid, administered through the Arizona Health Care Cost Containment System (AHCCCS), does not cover Trulicity for the majority of members as of 2026. The AHCCCS covered outpatient drug list prioritizes lower-cost diabetes agents including metformin, sulfonylureas, and select older insulin formulations. GLP-1 receptor agonists as a class face high prior-authorization barriers in the AHCCCS fee-for-service program.

Some managed care organizations contracting with AHCCCS, such as UnitedHealthcare Community Plan of Arizona and Banner University Family Care, maintain their own formularies. A small subset of those plans may cover semaglutide (Ozempic) or liraglutide (Victoza) in specific clinical circumstances with prior authorization, but dulaglutide specifically is generally excluded from AHCCCS formularies. Patients should call the member services number on their AHCCCS card and ask specifically whether dulaglutide (NDC prefix 00002) is covered under their plan's drug list.

The American Diabetes Association's 2024 Standards of Care state: "For patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, a GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended." [3] AHCCCS's exclusion of dulaglutide therefore creates a direct gap between clinical guidelines and coverage for Arizona's low-income diabetic population.

Patients denied AHCCCS coverage have the right to file a grievance within 90 days of a coverage denial. The AHCCCS appeals process is governed by A.R.S. §36-2903.01 and federal Medicaid managed care regulations at 42 C.F.R. §438.400-438.424. Documenting established cardiovascular disease with chart records strengthens an appeal significantly, given REWIND's cardiovascular outcome data. [4]

Is Compounded Dulaglutide Legal in Arizona?

Compounded dulaglutide is legal in Arizona when prepared by a state-licensed 503A compounding pharmacy under a valid patient-specific prescription from a licensed prescriber. The Arizona State Board of Pharmacy regulates 503A pharmacies under A.R.S. §32-1970 and the federal Drug Quality and Security Act of 2013. [5]

A 503B outsourcing facility, by contrast, cannot legally compound dulaglutide because dulaglutide is not on the FDA's 503B drug shortage list and has never been designated as a drug in shortage under section 506E of the Federal Food, Drug, and Cosmetic Act. The FDA's guidance on compounding of approved drugs is explicit on this point: bulk compounding of a drug that is commercially available and not in shortage from 503B facilities is impermissible. [6]

503A pharmacies operate under a different legal framework. They may compound dulaglutide if a licensed physician, nurse practitioner, or physician assistant in Arizona writes a prescription that is individualized to a specific patient. The prescription cannot be for office stock. Arizona NPs and PAs prescribing compounded GLP-1 agents must hold full prescriptive authority under their respective licensing boards (Arizona State Board of Nursing and Arizona Regulatory Board of Physician Assistants).

Pricing for compounded dulaglutide at Arizona 503A pharmacies varies widely. Some telehealth-affiliated pharmacies have priced compounded dulaglutide peptide preparations at $150-$300 per month, though patients should confirm the active pharmaceutical ingredient source, the pharmacy's PCAB accreditation status, and whether the formulation has been independently tested for potency, sterility, and endotoxins. The Arizona State Board of Pharmacy's license lookup tool (azpharmacy.gov) allows verification of a compounding pharmacy's status before purchase.

One practical risk: the compounded product is not Trulicity. It is a dulaglutide-containing preparation that has not undergone the same manufacturing controls as the FDA-approved drug. The FDA has issued multiple warning letters to compounding facilities producing GLP-1 analogs under substandard conditions. [7]

Which Insurance Plans Cover Trulicity in Arizona?

Most commercial insurance plans available through the Arizona Health Insurance Marketplace, employer-sponsored plans, and Medicare Part D cover Trulicity at some tier, though the specific cost-sharing varies considerably. The three most common coverage patterns in Arizona for 2026 are outlined below.

Employer-sponsored commercial insurance. Blue Cross Blue Shield of Arizona, Cigna, Aetna, and UnitedHealthcare all include dulaglutide on at least one formulary tier across their Arizona employer plan portfolios. Most place it on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), producing member copays of $60-$150 per fill before deductible and $30-$80 after deductible in a typical plan year. Prior authorization requiring A1c documentation and evidence of metformin trial is common.

Marketplace (ACA) plans in Arizona. Covered California does not operate in Arizona. Arizona uses HealthCare.gov. Most silver and gold ACA plans from Ambetter of Arizona (Centene), Blue Cross Blue Shield of Arizona Advantage, and Oscar Health list at least one GLP-1 agent, often semaglutide, as a covered preferred alternative. Dulaglutide appears on some but not all Marketplace formularies. Patients should run the plan's drug search tool at HealthCare.gov using the generic name dulaglutide before enrolling.

Medicare Part D in Arizona. CMS does not restrict plans from covering GLP-1 agents for type 2 diabetes under Part D, and most standard Part D plans available in Arizona cover dulaglutide with prior authorization. The Part D out-of-pocket cap of $2,000 effective January 1, 2025 under the Inflation Reduction Act meaningfully reduces the annual burden for Medicare patients who clear their deductible. [8] Patients in the coverage gap no longer face the catastrophic tier under the 2025 redesign. The Medicare Prescription Payment Plan (M3P) also allows spreading the annual $2,000 cap across twelve monthly installments for cash-flow management.

How the Eli Lilly Savings Card Works in Arizona

Eli Lilly offers two distinct savings programs for Trulicity, and Arizona patients qualify for both depending on insurance status.

The Trulicity Savings Card (commercially insured patients). Patients with commercial insurance, including employer plans and ACA Marketplace plans, may pay as little as $25 per month for a 30-day supply or $50 per month for a 90-day supply using Lilly's savings card. The card is available at TrulicitySavings.com. Eligibility requires that the patient is not enrolled in any federal or state government insurance program, including Medicare, Medicaid, TRICARE, or the VA. Income is not a factor for the commercial card. Patients using this card with a Tier 3 or Tier 4 plan effectively pay $25 regardless of their plan's negotiated rate, with Lilly covering the remaining cost-share up to $575 per month. [9]

Lilly Cares Foundation Patient Assistance Program (uninsured or underinsured patients). Uninsured Arizona patients with household income at or below 400% of the federal poverty level may qualify for free Trulicity through the Lilly Cares Foundation. The application is completed online at LillyCares.com and requires proof of income. Processing typically takes 2-4 weeks, and approved patients receive medication shipped directly to their prescriber's office or a designated pharmacy.

The Lilly Insulin Value Program, while named for insulin products, does not apply to Trulicity. Arizona patients sometimes confuse the two programs. The savings card is specific to Trulicity and the other branded GLP-1 products in Lilly's portfolio.

Clinical Evidence Supporting Dulaglutide Use

Prescribers in Arizona recommending Trulicity over alternatives do so on the basis of a substantial clinical trial portfolio. The most consequential study is REWIND (Researching Cardiovascular Events With a Weekly Incretin in Diabetes), published in The Lancet in 2019.

REWIND enrolled 9,901 adults with type 2 diabetes (mean A1c 7.3%, mean age 66 years, 46% female) across 24 countries. Participants received dulaglutide 1.5 mg weekly or placebo. After a median follow-up of 5.4 years, dulaglutide reduced the primary composite endpoint of major adverse cardiovascular events (MACE: nonfatal MI, nonfatal stroke, or cardiovascular death) by 12% relative to placebo (HR 0.88 to 95% CI 0.79-0.99, P<0.026). [4] The absolute risk reduction was 1.4 percentage points. 69% of REWIND participants had no prior cardiovascular disease at enrollment, a broader population than LEADER (liraglutide) or SUSTAIN-6 (semaglutide), suggesting dulaglutide's cardiovascular benefit extends to primary prevention in high-risk diabetic patients.

A1c reduction in the AWARD clinical program was consistent across doses. AWARD-11 (N=1,842) demonstrated that dulaglutide 3 mg and 4.5 mg reduced A1c by 1.9% and 2.0% respectively from baseline at 36 weeks, compared with 1.4% for the 1.5 mg dose. [10] Body weight reduction was 4.3 kg at 4.5 mg vs. 2.7 kg at 1.5 mg at 36 weeks in that trial.

The FDA label for dulaglutide, updated in 2020 following REWIND, carries the indication: "to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors." [1]

Renal data from the REWIND trial are also clinically meaningful. Dulaglutide reduced new macroalbuminuria (the renal composite endpoint) by 15% relative to placebo (HR 0.85 to 95% CI 0.77-0.93). [4] This is particularly relevant for Arizona's population, given that Arizona has one of the highest rates of end-stage renal disease from diabetic nephropathy among southwestern states, according to CDC surveillance data. [11]

Telehealth Access to Trulicity in Arizona

Arizona allows telehealth prescribing of Schedule-exempt drugs, including Trulicity, without a prior in-person visit, provided the prescriber-patient relationship meets the state's standard of care requirements. The Arizona Telemedicine Act (A.R.S. §36-3601) defines telehealth broadly and does not require a physical examination for every new prescription as long as the prescriber can gather sufficient clinical information through synchronous audio-video. [12]

This matters because Arizona's rural counties, including Navajo, Apache, Greenlee, and La Paz, have limited endocrinology access. A telehealth visit with an Arizona-licensed physician or NP can result in a Trulicity prescription sent to a local retail pharmacy or, where appropriate, to a licensed compounding pharmacy.

HealthRX clinicians prescribe dulaglutide via telehealth for Arizona patients who meet clinical criteria: type 2 diabetes with inadequate glycemic control on oral agents, or established or high-risk cardiovascular disease consistent with the REWIND-defined population. Patients outside those criteria may be candidates for other GLP-1 agents with weight-loss indications, such as semaglutide 2.4 mg (Wegovy), which produced 14.9% mean weight loss at 68 weeks in the STEP-1 trial (N=1,961) vs. 2.4% placebo. [13]

The HealthRX Arizona GLP-1 Access Framework classifies Arizona patients into four tiers based on insurance type and cardiovascular risk:

• Tier 1 (commercial insurance, established CVD): Trulicity savings card plus prior authorization support; target copay $25/month.
• Tier 2 (commercial insurance, no CVD): Trulicity savings card or semaglutide per formulary preference; target copay $25-$50/month.
• Tier 3 (AHCCCS/uninsured, income <400% FPL): Lilly Cares application or 503A compounded dulaglutide; target cost $0-$200/month.
• Tier 4 (Medicare Part D): Use 2025 $2,000 out-of-pocket cap plus M3P installment plan; target annual cap $2,000.

Arizona-Specific Considerations for Diabetic Patients

Arizona's diabetes burden exceeds the national average. The CDC reports that 11.4% of Arizona adults have diagnosed diabetes, compared with 10.5% nationally. [11] Pima County has some of the highest rates of type 2 diabetes in the country, partly attributable to the Pima Indian population, among whom prevalence of type 2 diabetes exceeds 50% in adults. [14]

The Arizona Department of Health Services runs the Diabetes Prevention and Control Program (ADHS DPCP), which coordinates with federally qualified health centers (FQHCs) across the state to provide medication access navigation. FQHCs operate under Section 340B of the Public Health Service Act, which allows them to purchase outpatient drugs at significantly reduced prices. An Arizona patient receiving care at a 340B-covered FQHC, such as El Rio Community Health Center in Tucson or Sunset Community Health Center in Peoria, may access Trulicity at 340B pricing through that facility's in-house or contract pharmacy. [15]

The 340B price for dulaglutide is not publicly disclosed, but CMS ceiling prices for covered entities are substantially below the $931 list price. Patients should ask their FQHC provider whether the facility participates in 340B for outpatient prescriptions.

Side Effects and Monitoring Relevant to Cost Decisions

Prescribers and patients in Arizona weighing the cost of Trulicity against alternatives should understand that the drug's tolerability profile affects adherence, which in turn affects cost-effectiveness. The most common adverse effects are gastrointestinal: nausea (12.4% at 0.75 mg, 21.1% at 1.5 mg in the AWARD-5 trial), diarrhea, and vomiting. [16] Most GI symptoms peak during the first four weeks and resolve by week 16 in the majority of patients.

Pancreatitis is a labeled warning. The incidence in clinical trials was low (0.11 per 100 patient-years for dulaglutide vs. 0.23 for comparators in a pooled analysis), but patients with a personal or family history of medullary thyroid carcinoma or MEN2 should not use any GLP-1 receptor agonist, per the FDA label. [1]

Injection site reactions are uncommon with the Trulicity single-dose pen, occurring in <1% of trial participants across the AWARD program, reflecting the pen's fine-gauge needle and automated injection mechanism. [1] The convenience of weekly dosing versus daily injections (as with liraglutide) is a legitimate adherence factor that can improve real-world cost-effectiveness despite the similar list price.

Monitoring recommendations from the American Diabetes Association include A1c every three months until at goal, then every six months; renal function annually; and thyroid palpation at each visit for patients on GLP-1 agents. [3]

What to Do Before Your First Arizona Trulicity Prescription

The practical sequence for a new Arizona patient pursuing Trulicity is straightforward. First, confirm insurance coverage by calling the member services number on your card and asking specifically: "Is dulaglutide (Trulicity) covered on my formulary, and what are the prior authorization requirements?" Get the answer in writing via the insurer's secure messaging portal if possible.

Second, if commercial insurance covers Trulicity, register for the Lilly savings card at TrulicitySavings.com before picking up the first prescription. The card activates immediately online.

Third, if AHCCCS or no insurance applies, ask your prescriber to complete a Lilly Cares application at the time of your appointment. Processing takes 2-4 weeks. A bridge supply from a 503A Arizona compounding pharmacy may be appropriate in the interim if the prescriber determines that a compounded preparation is clinically appropriate for you specifically.

Fourth, ask your pharmacy to run the prescription through both your insurance and a GoodRx or SingleCare coupon simultaneously. In some edge cases, the coupon price at a particular chain beats the post-deductible insurance price during the first months of a plan year.

The REWIND trial's cardiovascular outcome data support early initiation of dulaglutide in patients with type 2 diabetes and cardiovascular risk factors: the hazard ratio for MACE reached 0.88 at a median 5.4-year follow-up, with benefits beginning to diverge from placebo by month 12. [4] Delaying initiation to manage cost logistics, when savings mechanisms are available, carries its own clinical tradeoff.